Author + information
- Tabassome Simona,b,
- Etienne Puymirata,b,
- Francois Schielea,b,
- Guillaume Caylaa,b,
- Loic Bellea,b,
- Gilles Lemeslea,b,
- Bernard Jouvea,b,
- Meyer Elbaza,b and
- Nicolas Danchina,b
Background: Long-term data in patients needing oral anticoagulants after AMI are scarce. We assessed 12-month and 3-year mortality in AMI survivors, according to use of anticoagulants and combination therapy at discharge from index MI.
Methods: The French FAST-MI 2010 registry collected information on all patients admitted for AMI in 76% of French institutions at the end of 2010. Of 4169 patients included, 4023 survived the hospital phase and had prescription of discharge medications recorded. Of those, 3805 had antiplatelet therapy (APT) without anticoagulants (OAC) (Gr1), 108 (2.7%) had OAC alone or with single antiplatelet therapy (Gr2), and 110 (2.7%) having triple antithrombotic therapy (OAC+DAPT) (Gr 3).
Results: Baseline characteristics differed markedly between the 3 groups (table). At one year, adjusted HR for death, compared with Gr1 were 1.09 (0.64-1.88, P=NS) for Gr2, and 2.32 (1.31-4.12, P=0.004) for Gr3 patients. Three-year mortality was 89% for Gr1, compared with 78% for Gr 2 and 79% for Gr3. Adjusted hazard ratio for 3-year death (reference Gr 1) was 0.61 (0.39-0.96, P =0.032) for Gr2 and 1.55 (1.01-2.38, P=0.047) for Gr 3 patients. Similar trends were noted in patients with PCI at the acute stage.
Conclusions: These results suggest increased hazard in patients receiving triple antithrombotic therapy (OAC+DAPT) following PCI at the acute stage of AMI.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Antithrombotic Therapy in Ischemic Heart Disease
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1252-307
- 2017 American College of Cardiology Foundation